Abc 2011 2012 respiratory disorders part 2

72

Transcript of Abc 2011 2012 respiratory disorders part 2

Page 1: Abc 2011 2012 respiratory disorders part 2
Page 2: Abc 2011 2012 respiratory disorders part 2
Page 3: Abc 2011 2012 respiratory disorders part 2
Page 4: Abc 2011 2012 respiratory disorders part 2

etiology

• Precipitating conditions

• Previous PE

• CVS disease: HF, RV infarction, cardiomyopathy, corpulmonale

• Surgery: orthopedic, vascular, abdominal

• Cancer: ovarian, pancreatic, stomach, extrahepatic bile duct system

• Trauma (injury or burns): lower extremities, pelvis, hips

• Gynecologic status: pregnancy, postpartum, birth control pills, estrogen replacement therapy

Page 5: Abc 2011 2012 respiratory disorders part 2

Vascular endothelial injury, stasis, hypercoagulability

Thrombus formation Detaches and travels Embolus

Reaches the pulmonary arterial

system

Occlusion and blockage of a branch

of the pulmonary artery

An area of the lung is not being

perfused but is being ventilated

Pulmonary dead space

No participation in gas exchange

Increase work of breathing

Localized bronchoconstriction

Inflammatory/chemical mediators are released

Hypocarbia, hypoxia

Increased airway resistance

More bronchoconstriction

Compensatory shunting

hypoxemia

atelectasisPulmonary hypertension

vasoconstrictors

Page 6: Abc 2011 2012 respiratory disorders part 2
Page 7: Abc 2011 2012 respiratory disorders part 2

Assessment and diagnosis

• Impaired gas exchange related to V/Q mismatching or intrapulmonary shunting

• Acute pain related to transmission and perception of cutaneous, visceral, muscular, or ischemic impulses

• Powerlessness related to lack of control over current situation or disease progression

• Deficient knowledge: discharge regimen related to lack of previous exposure to information

Page 8: Abc 2011 2012 respiratory disorders part 2

Assessment and diagnosis

• Tachycardia, tachypnea

• Dyspnea, apprehension, increased pulmoniccomponent of the second heart sound

• Fever, rales, pleuritic chest pain, cough, evidence of DVT, and hemoptysis

• Syncope and hemodynamic instability

Page 9: Abc 2011 2012 respiratory disorders part 2

Assessment and diagnosis

• ABG• D-dimer – a fibrin degradation product that is a

small protein present in the blood after the clot has undergone fibrinolysis

• ECG• Chest radiography• Echocardiography• CT scan• V/Q scintigraphy• Pulmonary angiogram

Page 10: Abc 2011 2012 respiratory disorders part 2
Page 11: Abc 2011 2012 respiratory disorders part 2
Page 12: Abc 2011 2012 respiratory disorders part 2
Page 13: Abc 2011 2012 respiratory disorders part 2
Page 14: Abc 2011 2012 respiratory disorders part 2
Page 15: Abc 2011 2012 respiratory disorders part 2
Page 16: Abc 2011 2012 respiratory disorders part 2
Page 17: Abc 2011 2012 respiratory disorders part 2
Page 18: Abc 2011 2012 respiratory disorders part 2

Ventilation scintigraphy is a diagnostic procedure that portrays the regional and global distribution of an inhaled radioactive gas or radioaerosol within the lungs’ broncho-alveolar space. Perfusion scintigraphy is a diagnostic procedure that portrays the regional and global distribution of pulmonary artery blood flow. In combination V/Q is a useful procedure for the diagnosis of focal vascular, ventilatory or parenchymal pulmonary lesions.

Page 19: Abc 2011 2012 respiratory disorders part 2

• The most common indication: to determine the likelihood of pulmonary embolism• Less common indications:-evaluation of lungs transplantation-pre-operative lungs evaluation-evaluation of right-to-left shunt-tracheobronchial mucociliary escalator function and clearance-evaluation of alveolar function and clearance in patients with endothelial injury such as in AIDS, sarcoidosis, pneumonitis, alveolitis, ARDS

Page 20: Abc 2011 2012 respiratory disorders part 2
Page 21: Abc 2011 2012 respiratory disorders part 2

Medical management

• Prevention of recurrence - Administration of unfractionated or low-molecular-

weight heparin and warfarin (Coumadin)- Heparin has no effect on existing clot- Heparin should be adjusted to maintian the aPTT in a

range of 1.5 to 2.3 times the control- Warfarin should be started at the same time, and when

the INR reaches 3.0, the heparin should be discontinued

- The patient should remain on warfarin for 3 to 12 months depending on the patient’s risk for thromboembolic disease

Page 22: Abc 2011 2012 respiratory disorders part 2

Medical management

• Prevention of recurrence

- Interruption of the IVC is reserved for patients in whom anticoagulation is contraindicated

- The procedure involves placement of a percutaeneous venous filter (e.g., Greenfield filter) into the vena cava, usually below the renal arteries

- The filter prevents further thrombotic emboli form migrating into the lungs

Page 23: Abc 2011 2012 respiratory disorders part 2
Page 24: Abc 2011 2012 respiratory disorders part 2
Page 25: Abc 2011 2012 respiratory disorders part 2

Medical management

• Clot dissolution

- Thrombolytic agents had limited success, and is reserved for the patient with a massive PE and concomitant hemodynamic instability

- Either recombinant tissue-type plasminogenactivator (rt-PA) or streptokinase may be used

- Therapeutic window for thrombolytic therapy is 14 days

Page 26: Abc 2011 2012 respiratory disorders part 2

Medical management

• Clot dissolution

- Pulmonary embolectomy, often considered as a last resort, may be performed to surgically remove the clot

- Generally it is performed as an open procedure while the pattern is on cardiopulmonary bypass

Page 27: Abc 2011 2012 respiratory disorders part 2

Medical management

• Reversal of pulmonary hypertension

- Administration of inotropic agents and fluid

- Fluids should be administered to increase RV preload, which would stretch the RV and increase contractility, thus overcoming the elevated pulmonary arterial pressures

- Inotropic agents also cane be sued to increase contractility to facilitate an increase in CO

Page 28: Abc 2011 2012 respiratory disorders part 2

Nursing management

• Optimizing oxygenation

• Monitoring bleeding

• Patient education

Page 29: Abc 2011 2012 respiratory disorders part 2

Collaborative management

• Administer oxygen therapy

• Intubate patient

• Initiate mechanical ventilation

• Administer medications: thrombolytics, anticoagulants, bronchodilators, inotropic agents, sedatives, analgesics

• Administer fluids

• Position patient to optimize V/Q matching

• Maintain surveillance for complications: bleeding and acute lung injury

• Provide comfort and emotional support

Page 30: Abc 2011 2012 respiratory disorders part 2

Patient education

• Pathophysiology of the disease

• Specific etiology

• Precipitating factor modification

• Measures to prevent DVT

• Signs and symptoms of DVT

• Importance of taking medications

• Signs and symptoms of anticoagulant complications

• Measures to prevent bleeding

Page 31: Abc 2011 2012 respiratory disorders part 2

Status asthmaticus

Page 32: Abc 2011 2012 respiratory disorders part 2

Status asthmaticus

• Asthma – a COPD that is characterized by partially reversible airflow obstruction, airway inflammation, and hyperresponsiveness to a variety of stimuli

• Status asthmaticus – a severe asthma attack that fails to respond to conventional therapy with bronchodilators, which may result in acute respiratory failure

Page 33: Abc 2011 2012 respiratory disorders part 2

etiology

• URTI

• Allergen exposure

• Decreased in antiinflammatory medications

• Overreliance on bronchodilators

• Environmental pollutants

• Lack of access to health care

• Failure to identify worsening airflow obstruction

• Non-compliance with the health care regimen

Page 34: Abc 2011 2012 respiratory disorders part 2

First exposure to allergens (pollen, dust)

Absorbed into the tissues

Immune cells are triggerred

IgE antibodies are produced

IgE attach to mast cells, which gather in the lungs

Page 35: Abc 2011 2012 respiratory disorders part 2

Second exposure to the same allergen

Allergens attach to IgE antibodies

Mast cells degranulate

Inflammatory mediators (histamine) are released Bronchial smooth

muscles contract

Increase capillary permeability

Increase mucus secretion

Edema and inflammation of the bronchial walls

Bronchospasm

ObstructionWheezing and

dyspnea

Page 36: Abc 2011 2012 respiratory disorders part 2
Page 37: Abc 2011 2012 respiratory disorders part 2
Page 38: Abc 2011 2012 respiratory disorders part 2

Assessment and diagnosis

• Impaired gas exchange related to alveolar hypoventilation

• Ineffective breathing pattern related to musculoskeletal fatigue or neuromuscular impairment

• Ineffective airway clearance related to excessive secretions or abnormal viscosity of mucus

• Anxiety related to threat of biologic, psychologic, and/or social integrity

• Deficient knowledge: discharge regimen related to lack of previous exposure to information

Page 39: Abc 2011 2012 respiratory disorders part 2

Assessment and diagnosis

• Cough, wheezing and dyspnea

• As the attack continues, the patient develops tachypnea, tachycardia, diaphoresis, increased accessory muscle use, and pulsus paradoxusgreater than 25 mm Hg

• Decreased LOC, increasing inability to speak, significantly diminished or absent breath sounds, and inability to lie supine herald the onset of acute respiratory failure

Page 40: Abc 2011 2012 respiratory disorders part 2

Assessment and diagnosis

• ABG indicate hypocapnia and respiratory alkalosis caused by hyperventilation

• Hypoxemia and hypercapnia develops as the patient starts to fatigue

• Lactic acidosis may also occur

• Deterioration of PFT despite aggressive bronchodilator therapy is diagnostic of status asthmaticus

Page 41: Abc 2011 2012 respiratory disorders part 2

Assessment and diagnosis

• A PEFR less than 40% of predicted or an FEV1

(maximum volume of gas that the patient can exhale in 1 second) less than 20% of predicted indicates severe airflow obstruction, and the need for intubation with mechanical ventilation may be imminent

Page 42: Abc 2011 2012 respiratory disorders part 2

Medical management

• Bronchodilators – Beta2-agonists and anticholinergics

• Systemic corticosteroids

• Oxygen therapy

• Intubation and mechanical ventilation

Page 43: Abc 2011 2012 respiratory disorders part 2

Bronchodilators – B2-agonists

• Can be administered by nebulizer or metered-dose inhaler (MDI)

• Usually a larger and more frequent doses are given, and the drug is titrated to the patient’s response

• Xanthines are not recommended• Studies are being focused on the bronchodilating

abilities of magnesium• Magnesium is still inferior to B2-agonists, but may be

beneficial to patients who are refractory to conventional therapy

• A bolus of 1 to 4g of IV Mg given over 10 to 40 minutes has been reported to produce desirable effects

Page 44: Abc 2011 2012 respiratory disorders part 2

anticholinergics

• Not very effective by themselves

• Used in conjunction with Beta-agonists (synergistic effect)

• Studies are evaluating the effects of leukotrieneinhibitors (zafirlukast, montelukast, and zileuton) in the treatment of status asthmaticus

• Studies have shown that leukotriene inhibitors may be beneficial in those patients who are refractory to B2-agonists

Page 45: Abc 2011 2012 respiratory disorders part 2

Systemic corticosteroids

• IV or oral

• Limit iflammation, decrease mucus production, and potentiate B2-agonists

• Usually takes 6 to 8 hours for the effects to become evident

Page 46: Abc 2011 2012 respiratory disorders part 2

Oxygen therapy

• Supplemental oxygen for initial treatment of hypoxemia

• High-flow oxygen therapy to keep the patient’s SpO2 greater than 92%

Page 47: Abc 2011 2012 respiratory disorders part 2

Intubation and mechanical ventilation

• Indications for mechanical ventilation:1. Cardiac or respiratory arrest2. Disorientation3. Failure to respond to bronchodilator therapy4. Exhaustion• Avoid high inflation pressures because they can result in

barotrauma• PEEP monitoring is important because the patient is prone to

air trapping• Patient-ventilator asynchrony also can occur and can be a

major problem• Sedation and neuromuscular paralysis may be necessary to

allow for adequate ventilation

Page 48: Abc 2011 2012 respiratory disorders part 2
Page 49: Abc 2011 2012 respiratory disorders part 2
Page 50: Abc 2011 2012 respiratory disorders part 2
Page 51: Abc 2011 2012 respiratory disorders part 2

Nursing management

• Optimizing oxygenation and ventilation

• Providing comfort and emotional support

• Maintaining surveillance for complications

Page 52: Abc 2011 2012 respiratory disorders part 2

Patient education

• Pathophysiology of the disease

• Specific etiology

• Early warning signs of worsening airflow obstruction

• treatment of attacks

• Importance of taking prescribed medications and avoidance of OTC asthma medications

• Correct use of an inhaler (with and without spacer)

Page 53: Abc 2011 2012 respiratory disorders part 2
Page 54: Abc 2011 2012 respiratory disorders part 2
Page 55: Abc 2011 2012 respiratory disorders part 2
Page 56: Abc 2011 2012 respiratory disorders part 2

Patient education

• Correct use of peak flow meter

• Removal or avoidance of environmental triggers

• Measures to prevent pulmonary infections

• Signs and symptoms of pulmonary infections

• Importance of participating in pulmonary rehabilitation program

Page 57: Abc 2011 2012 respiratory disorders part 2

Acute respiratory distress syndrome

Page 58: Abc 2011 2012 respiratory disorders part 2

ards

A form of pulmonary edema that can quickly lead to acute respiratory failure

Also known as shock or stiff, white or Da Nang lung

Difficult to diagnose and can be fatal within 48 hours

Severe form of Acute Lung Injury

Page 59: Abc 2011 2012 respiratory disorders part 2

Phase 1

Phase 2

Phase 3 Phase 4

Phase 5Phase 6

Page 60: Abc 2011 2012 respiratory disorders part 2

H5N1 and A(H1N1)

• H – hemagglutinin

• N - enzyme on the surface of influenza viruses that enables the virus to be released from the host cell.

• Drugs that inhibit neuraminidase are used to treat influenza.

Page 61: Abc 2011 2012 respiratory disorders part 2

Phase 1 – injury reduces normal blood flow to the lungs

Platelets aggregate

Release of histamine, serotonin and bradykinin

Phase 2 – inflammation of alveolocapillary membrane

Capillary membrane permeability is increased

Fluid shifts from intravascular space into the interstitial space

Phase 3 - Leakage of protein and more fluids

Interstitial osmotic pressure increases

Page 62: Abc 2011 2012 respiratory disorders part 2

Pulmonary edema

Phase 4 - decrease blood flow to the lungs

Increase fluid in the alveoli

Surfactant is damaged

Impairs type 2 pneumocytes to produce more surfactant

Alveoli collapse

Interstitial osmotic pressure increases

Impeding gas exchange

Decreasing lung compliance

Page 63: Abc 2011 2012 respiratory disorders part 2

Phase 5 – oxygen cannot cross the alveolocapillary membrane but carbon dioxide can

Carbon dioxide is lost through exhalation

Oxygen and carbon dioxide levels decrease in the blood

Fibrosis

Phase 6 – pulmonary edema worsens

Decreasing lung compliance

Page 64: Abc 2011 2012 respiratory disorders part 2

Causes of ARDS

• Shock

• Sepsis

• Trauma

• Trauma-related factors: fat emboli, pulmonary contusions, and multiple transfusions may increase the likelihood that microemboli will develop

Page 65: Abc 2011 2012 respiratory disorders part 2

Assessment and diagnosis

• Impaired gas exchange related to V/Q mismatching or intrapulmonary shunting

• Decreased cardiac output related to alterations in preload

• Imbalanced nutrition: less than body requirements related to lack of exogenous nutrients or increased metabolic demand

• Anxiety related to threat to biologic, psychologic, and/or social integrity

• Compromised family coping related to critically ill family member

Page 66: Abc 2011 2012 respiratory disorders part 2

Assessment and diagnosis

• Tachypnea, restlessness, apprehension, and moderate increase in accessory muscle use – exudative pahse

• Agitation, dyspnea, fatigue, excessive accessory muscle use, and fine crackles as respiratory failure –fibrinolytic phase

• ABG1. Low PaO2 despite increases in supplemental O2

(refractory hypoxemia)2. Low PaCO2 initially, but eventually increases as the

patient fatigues3. The pH is high initially but decreases as respiratory

acidosis develops

Page 67: Abc 2011 2012 respiratory disorders part 2

Assessment and diagnosis

• Chest x-ray

1. Initially, it is normal

2. After 48 hours: diffuse patchy interstitial and alveolar infiltrates appear

3. Progression to multifocal consolidation of the lungs, which as a “white out” on the chest x-ray film

Page 68: Abc 2011 2012 respiratory disorders part 2
Page 69: Abc 2011 2012 respiratory disorders part 2
Page 70: Abc 2011 2012 respiratory disorders part 2

Management

• A – antibiotics

• R – respiratory support

• D – diuretics

• S – situate in the prone position

Page 71: Abc 2011 2012 respiratory disorders part 2

Medical management

• Ventilation

1. Low tidal volume

2. Permissive hypercapnia

3. Pressure control ventilation

4. Inverse ratio ventilation

5. Oxygen therapy

6. PEEP

7. Tissue perfusion

Page 72: Abc 2011 2012 respiratory disorders part 2

Nursing management

• Optimizing oxygenation and ventilation

• Providing comfort and emotional support

• Maintaining surveillance for complications